Skip to main
FOLD
FOLD logo

Amicus Therapeutics (FOLD) Stock Forecast & Price Target

Amicus Therapeutics (FOLD) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Amicus Therapeutics Inc. has demonstrated strong financial performance with Galafold sales experiencing consistent double-digit year-over-year growth, indicating robust market demand and the potential for sustained revenue generation. The company’s outlook is further bolstered by expectations of a growing addressable Fabry disease market, driven by advancements in diagnostic testing through artificial intelligence and machine learning technologies. Additionally, promising results from Atacicept in treating immunoglobulin A nephropathy (IgAN) highlight the company's commitment to expanding its pipeline of innovative therapies for rare diseases, suggesting a positive trajectory for future growth.

Bears say

Amicus Therapeutics Inc faces a negative outlook primarily due to the anticipated limited efficacy of its drug sparsentan in treating FSGS patients with high levels of MCP-1, a factor known to correlate with deteriorating kidney function and increased proteinuria. Additionally, despite acknowledging a sizeable total addressable market (TAM) of approximately 40,000 patients in the U.S. and a lack of FDA-approved therapies, the company's potential in this area appears underestimated by investors. This discrepancy between potential market opportunity and the projected drug performance raises concerns about the company's ability to deliver expected financial returns.

Amicus Therapeutics (FOLD) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amicus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amicus Therapeutics (FOLD) Forecast

Analysts have given Amicus Therapeutics (FOLD) a Buy based on their latest research and market trends.

According to 8 analysts, Amicus Therapeutics (FOLD) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amicus Therapeutics (FOLD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.